» Articles » PMID: 17164132

Role of Epoxyeicosatrienoic Acids in Protecting the Myocardium Following Ischemia/reperfusion Injury

Overview
Date 2006 Dec 14
PMID 17164132
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiomyocyte injury following ischemia-reperfusion can lead to cell death and result in cardiac dysfunction. A wide range of cardioprotective factors have been studied to date, but only recently has the cardioprotective role of fatty acids, specifically arachidonic acid (AA), been investigated. This fatty acid can be found in the membranes of cells in an inactive state and can be released by phospholipases in response to several stimuli, such as ischemia. The metabolism of AA involves the cycloxygenase (COX) and lipoxygenase (LOX) pathways, as well as the less well characterized cytochrome P450 (CYP) monooxygenase pathway. Current research suggests important differences with respect to the cardiovascular actions of specific CYP mediated arachidonic acid metabolites. For example, CYP mediated hydroxylation of AA produces 20-hydroxyeicosatetraenoic acid (20-HETE) which has detrimental effects in the heart during ischemia, pro-inflammatory effects during reperfusion and potent vasoconstrictor effects in the coronary circulation. Conversely, epoxidation of AA by CYP enzymes generates 5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acids (EETs) that have been shown to reduce ischemia-reperfusion injury, have potent anti-inflammatory effects within the vasculature, and are potent vasodilators in the coronary circulation. This review aims to provide an overview of current data on the role of these CYP pathways in the heart with an emphasis on their involvement as mediators of ischemia-reperfusion injury. A better understanding of these relationships will facilitate identification of novel targets for the prevention and/or treatment of ischemic heart disease, a major worldwide public health problem.

Citing Articles

Indirubin-3'-oxime as a dual-action agent: mitigating heat-induced male infertility in and inhibiting soluble epoxide hydrolase.

Phong N, Kim H, Zhao Y, Yeom E, Yang S J Enzyme Inhib Med Chem. 2025; 40(1):2447719.

PMID: 39840826 PMC: 11755746. DOI: 10.1080/14756366.2024.2447719.


Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics.

El-Serafi I, Steele S Adv Pharmacol Pharm Sci. 2024; 2024:4862706.

PMID: 38966316 PMC: 11223907. DOI: 10.1155/2024/4862706.


Overexpression of soluble epoxide hydrolase reduces post-ischemic recovery of cardiac contractile function.

Edin M, Gruzdev A, Bradbury J, Graves J, Muse G, Goulding D Biochem Pharmacol. 2024; 228:116237.

PMID: 38679211 PMC: 11410541. DOI: 10.1016/j.bcp.2024.116237.


Transient receptor potential ion channels and cerebral stroke.

Xu Q, Zou Y, Miao Z, Jiang L, Zhao X Brain Behav. 2022; 13(1):e2843.

PMID: 36527242 PMC: 9847613. DOI: 10.1002/brb3.2843.


The Role of CYP3A in Health and Disease.

Klyushova L, Perepechaeva M, Grishanova A Biomedicines. 2022; 10(11).

PMID: 36359206 PMC: 9687714. DOI: 10.3390/biomedicines10112686.


References
1.
Tu J, Austin P, Filate W, Johansen H, Brien S, Pilote L . Outcomes of acute myocardial infarction in Canada. Can J Cardiol. 2003; 19(8):893-901. View

2.
Gross G, Peart J . KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol. 2003; 285(3):H921-30. DOI: 10.1152/ajpheart.00421.2003. View

3.
Manuel D, Leung M, Nguyen K, Tanuseputro P, Johansen H . Burden of cardiovascular disease in Canada. Can J Cardiol. 2003; 19(9):997-1004. View

4.
Weiss J, Korge P, Honda H, Ping P . Role of the mitochondrial permeability transition in myocardial disease. Circ Res. 2003; 93(4):292-301. DOI: 10.1161/01.RES.0000087542.26971.D4. View

5.
Yellon D, Downey J . Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003; 83(4):1113-51. DOI: 10.1152/physrev.00009.2003. View